Stelara

DRUG6 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, Celltrion, Dong-A ST Co., Ltd., Alvotech Swiss AG, Biocon Biologics UK Ltd

Conditions

Autoimmune DiseasesHealthy VolunteersInflammatory DiseaseModerate to Severe Chronic Plaque PsoriasisPsoriasis

Phase 1

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

CompletedNCT05890118

RANI TherapeuticsHealthy Volunteers

Start: 2023-08-30End: 2023-11-28Updated: 2024-01-11

Phase 2

Personalized Therapies in Inflammatory Complex Disease

RecruitingNCT03651518

Assistance Publique - Hôpitaux de ParisAutoimmune Diseases, Inflammatory Disease

Start: 2020-10-20End: 2025-11-30Target: 32Updated: 2025-11-20

Phase 3

A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis

CompletedNCT04673786

CelltrionPsoriasis

Start: 2021-01-11End: 2022-05-12Updated: 2023-06-05

Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT04785326

Dong-A ST Co., Ltd.Moderate to Severe Chronic Plaque Psoriasis

Start: 2021-04-28End: 2022-11-16Updated: 2024-01-18

Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis

CompletedNCT04930042

Alvotech Swiss AGPsoriasis

Start: 2021-06-03End: 2022-10-11Updated: 2023-02-02

Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT05335356

Biocon Biologics UK LtdModerate to Severe Chronic Plaque Psoriasis

Start: 2022-06-28End: 2023-11-15Updated: 2025-09-12

Related Papers

Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.

2025-10-21

Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 study

Expert Opinion on Biological Therapy2025-07-251 citations

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

BioDrugs2023-11-2221 citations

Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis

Expert Opinion on Biological Therapy2023-07-1222 citations